---
title: "Ticagrelor versus Prasugrel After PCI for Acute Coronary Syndrome: Multinational Comparative Effec"
id: "medrxiv-23-comparative-effectiveness-of-ticagrelor-vs-prasugrel-in-patients-with-acute"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-23-comparative-effectiveness-of-ticagrelor-vs-prasugrel-in-patients-with-acute"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.13.26360416v1?rss=1"
published_at: "2026-08-17T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Ticagrelor versus Prasugrel After PCI for Acute Coronary Syndrome: Multinational Comparative Effec
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-23-comparative-effectiveness-of-ticagrelor-vs-prasugrel-in-patients-with-acute
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.13.26360416v1?rss=1)
- **Published At:** 2026-08-17T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This multinational retrospective new-user cohort study compared **ticagrelor** and **prasugrel** in adults with **acute coronary syndrome (ACS)** undergoing first percutaneous coronary intervention (**PCI**). - Data came from seven claims and electronic health record databases; prespecified diagnostics limited the primary meta-analysis to three databases that met balance and bias criteria. - The pooled primary analysis included 133,718 patients (ticagrelor 109,639; prasugrel 24,079) from one nationwide Korean claims database and two U.S. commercial claims databases. - The primary outcome was 1-year major adverse cardiovascular events (**MACE**: all-cause mortality, acute myocardial infarction, or stroke). Secondary outcomes included net adverse clinical events (**NACE**) and individual components including ischemic and hemorrhagic events. - Propensity scores were estimated with large-scale L1-regularized logistic regression and applied via stratification; database-specific hazard ratios were combined with a Bayesian random-effects meta-analysis. - The pooled hazard ratio (HR) for 1-year MACE for ticagrelor versus prasugrel was 1.28 (95% credible interval [CrI] 0.89–1.88), with substantial between-database heterogeneity; no statistically credible differences were observed for NACE, all-cause or cardiovascular mortality, ischemic or hemorrhagic events, AMI, stroke, or GI bleeding. - A post hoc meta-analysis restricted to the two U.S. databases yielded a pooled HR for 1-year MACE of 1.49 (95% CrI 1.05–2.10). - Sensitivity analyses using alternative time-at-risk definitions and propensity score matching were consistent with primary findings. - The study notes substantial cross-database heterogeneity and calls for further investigation into context-specific comparative effectiveness and safety; the report is a preprint and not peer-reviewed. - Patient-level data are not publicly available; analytic code is publicly accessible via study repositories. Conflicts of interest and institutional approvals are reported in the manuscript.
## Clinical Analysis & Structured Key Points
Comparative Effectiveness of Ticagrelor vs. Prasugrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention | medRxiv Skip to main content Comparative Effectiveness of Ticagrelor vs. Prasugrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention View ORCID Profile Chang Hoon Han , Anna Ostropolets , Clair Blacketer , Christophe G. Lambert , Ben S. Gerber , Jose D Posada , Farnoosh H. Sheikhi , justin Petucci , Thamir M Alshammari , View ORCID Profile Marc A. Suchard , View ORCID Profile Michael E Matheny , Christianus Heru Setiawan , Mereeja Varghese , Aamirah Vadsariya , Musa Ali Rizvi , View ORCID Profile Behnood Bikdeli , View ORCID Profile Seng Chan You doi: https://doi.org/10.64898/2026.08.13.26360416 Chang Hoon Han 1 Yonsei University College of Medicine, KOREA, REPUBLIC OF; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Chang Hoon Han Anna Ostropolets 2 Johnson and Johnson, UNITED STATES; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Clair Blacketer 2 Johnson and Johnson, UNITED STATES; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Christophe G. Lambert 3 University of New Mexico Health Sciences Center, UNITED STATES; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ben S. Gerber 4 University of Massachusetts Medical School, UNITED STATES; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jose D Posada 5 Stanford University School of Medicine, UNITED STATES; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Farnoosh H. Sheikhi 6 Stanford University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site justin Petucci 7 Institute for Computational and Data Sciences AND Clinical and Translational Sciences Institute, UNITED STATES; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Thamir M Alshammari 8 King Saudi University, UNITED STATES; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Marc A. Suchard 9 University of California Los Angeles Extension; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Marc A. Suchard Michael E Matheny 10 Vanderbilt University Medical Center, UNITED STATES; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Michael E Matheny Christianus Heru Setiawan 11 School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan, UNITED STATES; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Mereeja Varghese 12 The University of Texas Southwestern Medical Center, TAIWAN; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Aamirah Vadsariya 12 The University of Texas Southwestern Medical Center, TAIWAN; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Musa Ali Rizvi 13 The University of Texas Southwestern Medical Center Cardiology Division, UNITED STATES; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Behnood Bikdeli 14 Brigham and Women's Hospital, Harvard Medical School, UNITED STATES Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Behnood Bikdeli Seng Chan You 1 Yonsei University College of Medicine, KOREA, REPUBLIC OF; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Seng Chan You For correspondence: chandryou{at}yuhs.ac Abstract Info/History Metrics Data/Code Preview PDF Abstract Background: Ticagrelor and prasugrel are recommended P2Y 12 inhibitors for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), yet uncertainty persists regarding their direct comparative evidence and guideline recommendations differ. Methods: We conducted a multinational retrospective new-user cohort study across 7 claims and electronic health record databases. Adults with ACS undergoing first PCI who initiated ticagrelor or prasugrel were included; patients with prior major ischemic or hemorrhagic events or oral anticoagulant use were excluded. The primary outcome was 1-year major adverse cardiovascular events (MACE: all-cause mortality, acute myocardial infarction, or stroke). Secondary outcomes included net adverse clinical events (NACE) and individual components. Propensity scores were estimated using large-scale L1-regularized logistic regression and applied through stratification. Prespecified diagnostics (covariate balance, empirical equipoise, and systematic error) determined eligibility of each database for inclusion in meta-analysis. Database-specific hazard ratios (HRs) were combined using Bayesian random-effects meta-analysis. Results: Among 7 participating databases, 3 met prespecified diagnostic criteria and were included in the primary meta-analysis, comprising 133,718 patients from one nationwide Korean claims database and two U.S. commercial claims databases (ticagrelor, 109,639; prasugrel, 24,079). For 1-year MACE, the pooled HR for ticagrelor versus prasugrel was 1.28 (95% credible interval [CrI], 0.89-1.88), with substantial between-database heterogeneity. Sensitivity analyses across alternative time-at-risk definitions and propensity score matching were consistent. No statistically credible differences were observed for NACE (HR 1.23, CrI 0.88-1.75), all-cause mortality (HR 1.17, CrI 0.78-1.77), cardiovascular mortality (HR 1.23, CrI 0.81-1.87), ischemic events (HR 1.28, CrI 0.88-1.90), hemorrhagic events (HR 1.01, CrI 0.72-1.39), acute myocardial infarction (HR 1.30, CrI 0.88-1.94), stroke (HR 1.09, CrI 0.73-1.58), or gastrointestinal bleeding (HR 1.04, CrI 0.77-1.41). In a post hoc meta-analysis restricted to the two U.S. databases, the pooled HR for 1-year MACE was 1.49 (95% CrI 1.05-2.10). Conclusions: In this pre-specified multinational observational study, no statistically credible difference in 1-year MACE was observed between ticagrelor and prasugrel in patients with ACS undergoing PCI. However, substantial cross-database heterogeneity warrants further investigation into context-specific comparative effectiveness and safety. Competing Interest Statement Outside the submitted work, Dr. You reports grants from Daiichi Sankyo and VUNO. Dr. You receives compensation as an Associate Editor for JACC. Dr. You is a chief executive officer of PHI Digital Healthcare. Outside the submitted work, Dr. Bikdeli was supported by a Career Development Award from the American Heart Association and VIVA Physicians (#938814) and is supported by the American Heart Association (# 26BCDA1622734). Dr. Bikdeli was supported by the Scott Schoen and Nancy Adams IGNITE Award and by the Mary Ann Tynan Research Scientist award from the Mary Horrigan Connors Center for Women?s Health Research at Brigham and Women?s Hospital. Dr. Bikdeli is also supported by the Brigham and Women?s Hospital?s Eleanor and Miles Shore Award and by the APS Foundation of America. Dr. Bikdeli reports that he is a member of the Medical Advisory Board for the VascuLearn Network, and serves in the Data Safety and Monitoring Board of the NAIL-IT trial funded by the National Heart, Lung, and Blood Institute, and Translational Sciences. Outside the submitted work, Dr. Bikdeli is supported by grant U24- HL176626 (STAT-CAT trial, Co-Investigator) from the NHLBI. The manuscript and the findings do not necessarily represent the views of the National Institute of Health. Dr. Bikdeli receives compensation as an Associate Editor for the New England Journal of Medicine NEJM Clinician, as an Associate Editor for Thrombosis Research, and as an Executive Associate Editor for JACC, and is a Section Editor for Thrombosis and Haemostasis (no compensation). Dr. Ostroplets and Dr. Blacketer are employees of Johnson & Johnson (J&J) and shareholders of J&J stock. Clinical Trial N/A Clinical Protocols https://catalogues.ema.europa.eu/node/4452 Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was approved by the institutional review boards of Yonsei University Health System (4-2024-0718), UMass Chan Medical School (MOD00007080), and the University of New Mexico Health Sciences Center (26-282). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The patient-level data used in this study cannot be made publicly available. Additional aggregated study results may be available from the corresponding author upon reasonable request, subject to approval by the participating data partners and applicable data-use restrictions. Analytic code used for this study is publicly available through the study repositories cited in the manuscript. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Posted August 17, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Comparative Effectiveness of Ticagrelor vs. Prasugrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Comparative Effectiveness of Ticagrelor vs. Prasugrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Chang Hoon Han , Anna Ostropolets , Clair Blacketer , Christophe G. Lambert , Ben S. Gerber , Jose D Posada , Farnoosh H. Sheikhi , justin Petucci , Thamir M Alshammari , Marc A. Suchard , Michael E Matheny , Christianus Heru Setiawan , Mereeja Varghese , Aamirah Vadsariya , Musa Ali Rizvi , Behnood Bikdeli , Seng Chan You medRxiv 2026.08.13.26360416; doi: https://doi.org/10.64898/2026.08.13.26360416 Share This Article: Copy Citation Tools Comparative Effectiveness of Ticagrelor vs. Prasugrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Chang Hoon Han , Anna Ostropolets , Clair Blacketer , Christophe G. Lambert , Ben S. Gerber , Jose D Posada , Farnoosh H. Sheikhi , justin Petucci , Thamir M Alshammari , Marc A. Suchard , Michael E Matheny , Christianus Heru Setiawan , Mereeja Varghese , Aamirah Vadsariya , Musa Ali Rizvi , Behnood Bikdeli , Seng Chan You medRxiv 2026.08.13.26360416; doi: https://doi.org/10.64898/2026.08.13.26360416 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (605) Allergy and Immunology (891) Anesthesia (324) Cardiovascular Medicine (4720) Dentistry and Oral Medicine (471) Dermatology (403) Emergency Medicine (634) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1602) Epidemiology (15733) Forensic Medicine (32) Gastroenterology (1190) Genetic and Genomic Medicine (6929) Geriatric Medicine (723) Health Economics (1045) Health Informatics (4917) Health Policy (1416) Health Systems and Quality Improvement (1719) Hematology (571) HIV/AIDS (1319) Infectious Diseases (except HIV/AIDS) (16197) Intensive Care and Critical Care Medicine (1152) Medical Education (657) Medical Ethics (150) Nephrology (713) Neurology (7105) Nursing (358) Nutrition (1065) Obstetrics and Gynecology (1214) Occupational and Environmental Health (990) Oncology (3542) Ophthalmology (1025) Orthopedics (384) Otolaryngology (440) Pain Medicine (461) Palliative Medicine (138) Pathology (700) Pediatrics (1762) Pharmacology and Therapeutics (728) Primary Care Research (754) Psychiatry and Clinical Psychology (5776) Public and Global Health (9612) Radiology and Imaging (2357) Rehabilitation Medicine and Physical Therapy (1416) Respiratory Medicine (1232) Rheumatology (631) Sexual and Reproductive Health (759) Sports Medicine (571) Surgery (755) Toxicology (106) Transplantation (300) Urology (283)
## Related Clinical Research

- [Stepwise DAPT de-escalation vs standard DAPT after drug-coated balloon angioplasty in multivessel](https://medichelpline.com/clinical-feed/medrxiv-15-impact-of-stepwise-dual-antiplatelet-therapy-de-escalation-in-patients-with.md)
- [One-Year Outcomes of the ISAR SUMMIT Polymer-Free Everolimus-Eluting Stent in Real-World PCI](https://medichelpline.com/clinical-feed/medrxiv-15-one-year-safety-and-effectiveness-of-the-isar-summit-polymer-free-everolimus.md)
- [Semaglutide and Primary Prevention of MACCE in Obese Adults with T2DM and Rheumatoid Arthritis](https://medichelpline.com/clinical-feed/pubmed-42334436.md) (DOI: 10.1093/ehjcvp/pvag044)
- [Optimal DAPT Duration After PCI with Contemporary DES: Network Meta-analysis of RCTs](https://medichelpline.com/clinical-feed/plos-one-7-dual-antiplatelet-therapy-duration-after-percutaneous-coronary-intervention.md)
- [Genistein modifies the association between EASIX and estimated 10-year ASCVD risk](https://medichelpline.com/clinical-feed/plos-one-13-interaction-between-genistein-and-the-endothelial-activation-and-stress-index.md)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.